Chinese leading biopharmaceutical company, 3SBio Inc., announced today that Selecta Biosciences, Inc., the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of ...
Selecta Biosciences is laying off more than one-third of its workforce. The cuts come as Selecta seeks to eke out its cash reserves and advance a gout drug that disappointed investors in phase 2......